PsyBio’s intellectual property portfolio now includes seven pending provisionals and one pending non-provisional patent application Company has also initiated preclinical studies aimed at treating psychologic and neurologic conditions OXFORD, Ohio and COCONUT CREEK, Fla., Aug. 16, 2021 /CNW/ — PsyBio Therapeutics Corp. (TSXV: PSYB, OTCQB:PSYBF) (“PsyBio” or the “Company“)…


Previous articleKeeping Participants Safe in Psychedelic Research
Next articleMydecine Reports Second Quarter 2021 Financial Results and Provides Business Update